Abstract: The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.

Abstract: Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.

Abstract: The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.

Abstract: The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.

Abstract: The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.

Abstract: The invention is directed towards novel amino acid based compounds, which may be isotopically enriched, and methods of use of such compounds for characterizing one or more molecules of a sample by mass spectrometry, the method comprising: (a) reacting the one or more molecules with the compound; and (b) characterizing the one or more molecules by mass spectrometry.

Abstract: A method of fabricating a chromatographic column and columns produced by such a method are disclosed. The method includes: (a) obtaining a tube comprising two open ends and a lumen with a diameter of 75 microns or less extending between the two open ends; (b) depositing a liquid silicate composition into the tube lumen at a first open end of the tube; (c) forming a porous ceramic material from the composition in the tube lumen at a location near the first open end such that a space is formed between the ceramic material and the open end that is substantially free of the ceramic material; and (d) forming a tapered emitter having an orifice diameter of less than 3 microns at the first open end.

Abstract: The invention is directed towards novel amino acid based compounds, which may be isotopically enriched, and methods of use of such compounds for characterising one or more molecules of a sample by mass spectrometry, the method comprising: (a) reacting the one or more molecules with the compound; and (b) characterising the one or more molecules by mass spectrometry.

Abstract: The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.

Abstract: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens.

Abstract: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens.

Abstract: A method of fabricating a chromatographic column and columns produced by such a method are disclosed. The method includes: (a) obtaining a tube comprising two open ends and a lumen with a diameter of 75 microns or less extending between the two open ends; (b) depositing a liquid silicate composition into the tube lumen at a first open end of the tube; (c) forming a porous ceramic material from the composition in the tube lumen at a location near the first open end such that a space is formed between the ceramic material and the open end that is substantially free of the ceramic material; and (d) forming a tapered emitter having an orifice diameter of less than 3 microns at the first open end.

Abstract: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens.

Abstract: The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.

Abstract: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens.

Abstract: The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.

Abstract: The invention relates to a method for the detection and identification of amino acid modifications, such as phosphorylation, using a combination of affinity capture and mass-spectroscopy.

Abstract: The invention provides a method of priming T cells against tumor antigens comprising by obtaining naïve CD4+ or CD8+ T cells from at least one healthy individual, obtaining at least one protein or peptide from at least one cancerous cell; obtaining antigen presenting cells (APCs), culturing the APCs with the at least one protein or peptide, and adding the T cells to the culture of the APCs. The primed T cells can then be employed to identify the antigens or therapeutically as prophylaxis or treatment for cancers.